Obicetrapib

Obicetrapib has been studied in 30 papers since 2023: 9 trials in people, 1 in animals, 20 reviews; 22 in the past year. Its furthest trials in people are at phase 3. The newest story, Oct 24, 2026: “Obicetrapib did not raise blood sugar in pooled trials”.

InterventionPhase 3

30 papers study it2 more mention it54 findingsUpdated

PubChem

6 new papers in 30 daysSee all 32 papers on obicetrapib

At a glance

Obicetrapib slows plasma p-Tau217 increases in human trials in atherosclerotic cardiovascular disease; independent labs reproduce LDL reductions and HDL increases in humans. Adverse-event results generally show no clear effect, but a review reports fewer events. Authors report developer ties; registered trials across uses are company-sponsored, and some ended over a year ago without posted results.

54 findings in 23 papers from 2025 to 2026, 8 of them since April 2026

Independent labs found the same change in people. 12 independent labs in 8 countries; 19 trials, 5 about aging, 3 with no results posted.

“Obicetrapib also showed substantial improvements in HDL-C and ApoB.”
Efficacy and Safety of Oral Non-Statin Lipid-Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta-AnalysisEndocrinology, diabetes & metabolism2026doi:10.1002/edm2.70353

1 of its findings points the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 12 independent labs in 8 countries
  • 1 finding against
  • 19 trials, 5 about aging, 3 with no results posted
  • Funders: NewAmsterdam Pharma and 7 more
  • 27 of 47 findings with company ties
  • 19 of 19 trials sponsored by its developers
  • Human trial9
  • Animals1

11 studies gave obicetrapib to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on HbA1cLSMD -0.02%, 95% CI -0.04 to 0.00

down: Lowers the risk of new-onset diabetes6.4% versus 8.5%; adjusted OR 0.69, 95% CI 0.47-1.03

Review of trials52 weeks1,700 people pooledBothEuropean journal of preventive cardiology, Oct 24, 2026

up: Increases HDL-fraction lipophilic antioxidants

down: Decreases oxidized LDL

up: Increases HDL2 cholesterol

Trial8 weeks12 peopleJapanese participants; n = 12 per groupScientific reports, Oct 16, 2026

down: Decreases LDL-CMD -37.45

down: Decreases non-HDL-CMD -32.04

down: Decreases Apolipoprotein BMD -24.71

Review of trials3,512 people pooledPatient cohortsCardiology in review, Jun 29, 2026

down: Decreases estimated glomerular filtration rate reduction6.7 % vs. 8.7 % RR 0.77 [0.59, 1.00]

no change: Has no effect on blood pressure

no change: Has no effect on mortality

Review of trials365 days2,880 people pooledBothmean age 64 yearsOlder adults; HeFH or ASCVDAmerican journal of preventive cardiology, Mar 24, 2026

down: Decreases LDL cholesterol-36.3% placebo-adjusted change; 95% CI -42.2% to -30.4%

Randomized trial84 days354 peopleBothHeterozygous familial hypercholesterolemia on maximally tolerated lipid-lowering therapyNature medicine, Feb 27, 2026

What did studies of obicetrapib find?

28

Studies of obicetrapib measured 28 outcomes, among them LDL-C, LDL cholesterol and HDL-C.

LDL-C

downin humans6−33%

6 studies
  1. Obicetrapib decreases LDL-C in humans (-36.4% versus placebo).

    “Monotherapy produced a -36.4% LDL-C reduction versus placebo”

    Human trialPK-confirmed on-treatment patients with ASCVD or HeFH receiving maximum-tolerated lipid-lowering therapy; versus placebo84 days

    Pooled on treatment lipid lowering efficacy of the CETP inhibitor obicetrapib in phase III trials

    ESC Congress 2026 abstract

  2. Obicetrapib decreases LDL-C in humans (MD -37.45).

    “Obicetrapib significantly reduced low-density lipoprotein cholesterol [MD, -37.45 (95% CI, -43.76 to -31.15), P < 0.001]”

    Human trialn = 3,512

    Lipid-Lowering Efficacy and Safety of Obicetrapib Alone and as an Add on Therapy: A Meta-Analysis of Randomized Controlled Trials

    Cardiology in review

  3. Obicetrapib decreases LDL-C in humans (atherosclerosis cardiovascular disease) (-33%).

    “Obicetrapib significantly lowered LDL‐C by 33% and increased HDL‐C by 125% relative to placebo.”

    Human trialatherosclerosis cardiovascular disease12 monthsn = 1,727

    Effects of Obicetrapib, a Potent Oral CETP Inhibitor, on Alzheimer's Disease Biomarkers in 1727 Patients with cardiovascular disease

    AAIC 2025 abstract

  4. Obicetrapib decreases LDL-C in humans (on background statin therapy) (MD -37.36%; 95% CI -41.44 to -33.28).

    “Obicetrapib demostrated significantly greater reductions in LDL-C (mean difference [MD]: -37.36%; 95% CI: -41.44 to -33.28; p<0.00001)”

    Human trialon background statin therapy10 mg

    Evaluating Lipid-Lowering Efficacy Of Obicetrapib: An Updated Meta-Analysis of Clinical Trials

    AHA Scientific Sessions 2025 abstract

  5. Obicetrapib decreases LDL-C in humans (substantial reduction).

    “demonstrating substantial reductions in LDL-C, apolipoprotein B, non-HDL-C, and lipoprotein(a), alongside marked increases in HDL-C”

    Review

    CETP Renaissance with Obicetrapib

    Current atherosclerosis reports

  6. Obicetrapib decreases LDL-C in patients with dyslipidemia or ASCVD, pooled from RCTs (MSD -35.43 (95% CI -40.14 to -30.17)).

    “It reduced LDL-C (MSD: –35.43; 95% CI: –40.14 to –30.17; I2 = 93.26%)”

    Reviewin patients with dyslipidemia or ASCVD, pooled from RCTsn = 3,483

    Efficacy and Safety of Obicetrapib in Dyslipidemia or Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis

    AHA Scientific Sessions 2025 abstract

More on LDL-C

LDL cholesterol

downin humans6−32%

6 studies
  1. Obicetrapib decreases LDL cholesterol in humans (-36.3% placebo-adjusted change; 95% CI -42.2% to -30.4%).

    “obicetrapib treatment resulted in a placebo-adjusted change in LDL cholesterol of -36.3% (95% confidence interval -42.2% to -30.4%, P < 0.0001).”

    Human trialheterozygous familial hypercholesterolemia on maximally tolerated lipid-lowering therapy; compared with placebo10 mg daily84 daysn = 354

    Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial

    Nature medicine

  2. Obicetrapib decreases LDL cholesterol in humans (on top of statin therapy) (-33.17% (95% CI, -36.21 to -30.13)).

    “Obicetrapib resulted in a pooled LDL-C reduction of -33.17% (95% CI, -36.21 to -30.13) vs placebo”

    Human trialon top of statin therapy

    Comparative efficacy and safety of obicetrapib vs bempedoic acid on top of statin therapy: A network meta-analysis

    Journal of clinical lipidology

  3. Obicetrapib decreases LDL cholesterol in humans (statin-treated adults) (MD -27.29 mg/dL; 95% CI -33.65 to -20.93).

    “Obicetrapib, compared to placebo, was associated with a significantly greater reduction in LDL-C (MD: -27.29 mg/dL; 95% CI: -33.65 to -20.93; P < 0.0001)”

    Human trialstatin-treated adultsn = 3,386

    Obicetrapib in Patients with Dyslipidemia with or without Atherosclerotic Cardiovascular Disease Risk: A Meta-Analysis of Randomized Controlled Trials

    AHA Scientific Sessions 2025 abstract

  4. Obicetrapib decreases LDL cholesterol in humans (30–50% reduction; average reduction 0.92 mmol/l (35.4 mg/dl)).

    “The average LDL cholesterol reduction was 0.92 mmol/l (35.4 mg/dl), with amplified effects when combined with ezetimibe.”

    Review

    Beyond Traditional Lipid Lowering: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition

    European cardiology

  5. Obicetrapib decreases LDL cholesterol in humans (high-risk ASCVD patients on maximally tolerated lipid lowering therapy) (-31.75%).

    “Obicetrapib significantly reduced LDL-C (-31.75%), non-HDL-C (-29.35%), triglyceride (-5.61%), Lp(a) (-35.67%), ApoB (-19.37%), and increased HDL-C (+125.94%) with no difference in total cholesterol levels.”

    Reviewhigh-risk ASCVD patients on maximally tolerated lipid lowering therapy37% femalesn = 3,088

    Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis

    Vascular diseases (Paris, France)

  6. Obicetrapib decreases LDL cholesterol in humans (versus placebo) (MD -33.63 mg/dL; 95% CI [-44.10, -23.16]).

    “Obicetrapib showed the most significant reduction in LDL-C (MD -33.63 mg/dL; 95% CI [-44.10, -23.16])”

    Reviewversus placebon = 2,937

    Comparative efficacy of obicetrapib and anacetrapib in reducing low-density lipoprotein (LDL) levels: a network meta-analysis of clinical trials

    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences

More on LDL cholesterol

HDL-C

upin humans4+125%

4 studies
  1. Obicetrapib increases HDL-C in humans.

    “Obicetrapib also showed substantial improvements in HDL-C and ApoB.”

    Human trial

    Efficacy and Safety of Oral Non-Statin Lipid-Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta-Analysis

    Endocrinology, diabetes & metabolism

  2. Obicetrapib increases HDL-C in humans (MD +147.98).

    “HDL cholesterol [MD, +147.98 (95% CI, 129.23-166.54), P < 0.001]”

    Human trialn = 3,512

    Lipid-Lowering Efficacy and Safety of Obicetrapib Alone and as an Add on Therapy: A Meta-Analysis of Randomized Controlled Trials

    Cardiology in review

  3. Obicetrapib increases HDL-C in humans (atherosclerosis cardiovascular disease) (+125%).

    “Obicetrapib significantly lowered LDL‐C by 33% and increased HDL‐C by 125% relative to placebo.”

    Human trialatherosclerosis cardiovascular disease12 monthsn = 1,727

    Effects of Obicetrapib, a Potent Oral CETP Inhibitor, on Alzheimer's Disease Biomarkers in 1727 Patients with cardiovascular disease

    AAIC 2025 abstract

  4. Obicetrapib increases HDL-C in humans (on background statin therapy) (MD 156.21%; 95% CI 146.40% to 166.02%).

    “HDL-C levels in the obicetrapib group were significantly higher (MD: 156.21%; 95% CI: 146.40% to 166.02%; p<0.00001)”

    Human trialon background statin therapy10 mg

    Evaluating Lipid-Lowering Efficacy Of Obicetrapib: An Updated Meta-Analysis of Clinical Trials

    AHA Scientific Sessions 2025 abstract

More on HDL-C

HDL cholesterol

upin humans4

4 studies
  1. Obicetrapib increases HDL cholesterol in humans (statin-treated adults) (MD 70.96 mg/dL; 95% CI 64.71 to 77.20).

    “a significantly greater increase in HDL-C (MD: 70.96 mg/dL; 95% CI: 64.71 to 77.20; P < 0.0001)”

    Human trialstatin-treated adultsn = 3,386

    Obicetrapib in Patients with Dyslipidemia with or without Atherosclerotic Cardiovascular Disease Risk: A Meta-Analysis of Randomized Controlled Trials

    AHA Scientific Sessions 2025 abstract

  2. Obicetrapib increases HDL cholesterol in humans (More than 100% increase).

    “while elevating HDL cholesterol levels by more than 100%.”

    Review

    Beyond Traditional Lipid Lowering: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition

    European cardiology

  3. Obicetrapib increases HDL cholesterol in humans (versus placebo) (MD 154.33 mg/dL; 95% CI [132.73, 175.93]).

    “and the most significant increase in HDL-C (MD 154.33 mg/dL; 95% CI [132.73, 175.93]), outperforming anacetrapib.”

    Reviewversus placebon = 2,937

    Comparative efficacy of obicetrapib and anacetrapib in reducing low-density lipoprotein (LDL) levels: a network meta-analysis of clinical trials

    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences

  4. Obicetrapib increases HDL cholesterol in humans (MD +156.77 mg/dL, 95% CI [117.41; 196.13]).

    “HDL cholesterol increased markedly, with Obicetrapib showing superior efficacy”

    Review

    SAT-259 Comparative Efficacy of Anacetrapib and Obicetrapib: A Network Meta-Analysis of CETP Inhibitors

    ENDO 2025 abstract

More on HDL cholesterol

Adverse events

no changein humans3RR 0.96

3 studies
  1. Obicetrapib showed no clear effect on adverse events in humans (statin-treated adults).

    “there was no significant difference in total adverse events (AEs) (P= 0.4124), serious AEs (P= 0.3712), and AEs leading to discontinuation of medication (P=0.4035)”

    Human trialstatin-treated adultsn = 3,386

    Obicetrapib in Patients with Dyslipidemia with or without Atherosclerotic Cardiovascular Disease Risk: A Meta-Analysis of Randomized Controlled Trials

    AHA Scientific Sessions 2025 abstract

  2. Obicetrapib showed no clear effect on adverse events in humans (high-risk ASCVD patients on maximally tolerated lipid lowering therapy).

    “Obicetrapib was not associated with increased risk for any AE, AE leading to discontinuation, AKI, transaminase or CK elevation, and hypertension.”

    Reviewhigh-risk ASCVD patients on maximally tolerated lipid lowering therapyshort-term37% femalesn = 3,088

    Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis

    Vascular diseases (Paris, France)

  3. Obicetrapib showed no clear effect on adverse events in patients with dyslipidemia or ASCVD, pooled from RCTs (RR 0.96 (95% CI 0.76 to 1.21) for any adverse event).

    “Obicetrapib demonstrated a safety profile comparable to placebo.”

    Reviewin patients with dyslipidemia or ASCVD, pooled from RCTsn = 3,483

    Efficacy and Safety of Obicetrapib in Dyslipidemia or Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis

    AHA Scientific Sessions 2025 abstract

p-Tau217

downin humans3

3 studies
  1. Obicetrapib decreases p-Tau217 in humans (atherosclerosis cardiovascular disease) (1.1% obicetrapib vs. 4.8% with placebo).

    “Obicetrapib demonstrated significant attenuation of increase in the median plasma p ‐tau217 (1.1% obicetrapib vs. 4.8% with placebo; p =0.01)”

    Human trialatherosclerosis cardiovascular disease12 monthsn = 1,727

    Effects of Obicetrapib, a Potent Oral CETP Inhibitor, on Alzheimer's Disease Biomarkers in 1727 Patients with cardiovascular disease

    AAIC 2025 abstract

  2. Obicetrapib decreases p-Tau217 in humans (ASCVD; compared with placebo) (Adjusted mean increases 2.09% versus 4.94% with placebo).

    “Obicetrapib significantly attenuated p-tau217 increases compared to placebo (adjusted mean 2.09 % vs 4.94 %; P = 0.025).”

    Human trialASCVD; compared with placeboplasma10 mg daily12 months67.0 % were malesn = 1,535

    Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease

    The journal of prevention of Alzheimer's disease

  3. Obicetrapib decreases p-Tau217 in patients with high-risk ASCVD.

    “In BROADWAY, obicetrapib reduced p-tau217 progression across the study population, with effects most pronounced in APOE4 carriers.”

    Reviewin patients with high-risk ASCVD

    The emerging role of CETP inhibition in the prevention of Alzheimer's disease

    American journal of preventive cardiology

More on p-Tau217

Lipoprotein

downin humans2

2 studies
  1. Obicetrapib decreases lipoprotein in humans (Compared with control in pooled randomized controlled trials) (MD −40.74%; 95% CI −49.50 to −31.98).

    “Among non-Lp(a)-targeted therapies, obicetrapib produced a moderate reduction (MD, –40.74%; 95% CI, –49.50 to –31.98)”

    ReviewCompared with control in pooled randomized controlled trials

    Comparative Effects of Lipoprotein(a)-Targeted and Lipid-Modifying Therapies on Percent Change in Lipoprotein(a)

    AHA Scientific Sessions 2026 abstract

  2. Obicetrapib decreases lipoprotein in humans (Reduction by as much as 40–50%).

    “obicetrapib significantly reduces LDL cholesterol by 30-50%, apolipoprotein B by 20-30% and lipoprotein(a) by as much as 40-50%”

    Review

    Beyond Traditional Lipid Lowering: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition

    European cardiology

More on Lipoprotein

Oxidized LDL

downin humans2

2 studies
  1. Obicetrapib decreases oxidized LDL in humans (Japanese participants; n = 12 per group).

    “Obicetrapib robustly increased all antioxidant levels in the HDL fraction and decreased plasma levels of oxidized low-density lipoprotein.”

    Human trialJapanese participants; n = 12 per groupplasma2.5, 5, and 10 mg/d8 weeksn = 12

    Cholesteryl ester transfer protein (CETP) inhibition and high-density lipoprotein particle composition: consequences for atherogenesis and neurodegeneration

    Scientific reports

  2. Obicetrapib decreases oxidized LDL in Japanese participants.

    “decreased plasma levels of oxLDL at all doses”

    Human trialin Japanese participantsplasma2.5, 5, and 10 mg/d8 weeksn = 12

    Cholesteryl Ester Transfer Protein Inhibition and High-Density Lipoprotein Particle Composition: Consequences for Atherogenesis and Neurodegeneration

    Research SquarePreprint

More on Oxidized LDL

Non-HDL cholesterol

downin humans1downin mice1−53%

2 studies
  1. Obicetrapib decreases non-HDL cholesterol in humans (vs bempedoic acid on top of statin therapy) (-16.1% (95% CI, -19.1 to -13.1)).

    “Obicetrapib also showed a greater non-HDL-C reduction of -16.1% (95% CI, -19.1 to -13.1).”

    Human trialvs bempedoic acid on top of statin therapy

    Comparative efficacy and safety of obicetrapib vs bempedoic acid on top of statin therapy: A network meta-analysis

    Journal of clinical lipidology

  2. Obicetrapib decreases non-HDL cholesterol in mice (APOE*3-Leiden.CETP mice on Western-type diet) (-53%).

    “all interventions reduced non-HDL-C levels (obicetrapib: -53%; ezetimibe: -19%; combination: -75%)”

    AnimalsAPOE*3-Leiden.CETP mice on Western-type diet8 weeks

    Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL clearance and regress atherosclerosis on atorvastatin background

    Journal of lipid research

More on Non-HDL cholesterol

HbA1c

no changein humans1

1 study
  1. Obicetrapib showed no clear effect on HbA1c in humans (Without diabetes at baseline; compared with placebo) (LSMD -0.02%, 95% CI -0.04 to 0.00).

    “Obicetrapib did not increase HbA1c at week 52 vs placebo (LSMD -0.02%, 95% CI -0.04 to 0.00).”

    Human trialWithout diabetes at baseline; compared with placebo10 mg52 weeks38.8% womensn = 1,700

    Obicetrapib did not raise blood sugar in pooled trials

    European journal of preventive cardiology

More on HbA1c

HDL2 and CSF carotenoids and tocopherols

upin humans1

1 study
  1. Obicetrapib increases HDL2 and CSF carotenoids and tocopherols in humans (early Alzheimer's disease).

    “demonstrated that HDL2 and CSF carotenoid and tocopherol levels were increased by obicetrapib.”

    Human trialearly Alzheimer's diseaseplasma and cerebrospinal fluid10 mg/dn = 13

    Cholesteryl ester transfer protein (CETP) inhibition and high-density lipoprotein particle composition: consequences for atherogenesis and neurodegeneration

    Scientific reports

More on HDL2 and CSF carotenoids and tocopherols

HDL2 cholesterol

upin humans1

1 study
  1. Obicetrapib increases HDL2 cholesterol in humans (Japanese participants, low-dose group).

    “In specific analyses of the low-dose group, obicetrapib also raised HDL2 cholesterol, apoA1, S1P, apoM, and apoE.”

    Human trialJapanese participants, low-dose groupplasma2.5 mg/d8 weeksn = 12

    Cholesteryl ester transfer protein (CETP) inhibition and high-density lipoprotein particle composition: consequences for atherogenesis and neurodegeneration

    Scientific reports

More on HDL2 cholesterol

HDL-fraction lipophilic antioxidants

upin humans1

1 study
  1. Obicetrapib increases HDL-fraction lipophilic antioxidants in humans (Japanese participants; n = 12 per group).

    “Obicetrapib robustly increased all antioxidant levels in the HDL fraction”

    Human trialJapanese participants; n = 12 per groupplasma2.5, 5, and 10 mg/d8 weeksn = 12

    Cholesteryl ester transfer protein (CETP) inhibition and high-density lipoprotein particle composition: consequences for atherogenesis and neurodegeneration

    Scientific reports

More on HDL-fraction lipophilic antioxidants

Apolipoprotein B

downin humans1

1 study
  1. Obicetrapib decreases Apolipoprotein B in humans (MD -24.71).

    “apolipoprotein B [MD, -24.71 (95% CI, -30.79 to -18.63), P < 0.001]”

    Human trialn = 3,512

    Lipid-Lowering Efficacy and Safety of Obicetrapib Alone and as an Add on Therapy: A Meta-Analysis of Randomized Controlled Trials

    Cardiology in review

More on Apolipoprotein B

Non-HDL-C

downin humans1

1 study
  1. Obicetrapib decreases non-HDL-C in humans (MD -32.04).

    “non-high-density lipoprotein (HDL) cholesterol [MD, -32.04 (95% CI, -38.49 to -25.60), P < 0.001]”

    Human trialn = 3,512

    Lipid-Lowering Efficacy and Safety of Obicetrapib Alone and as an Add on Therapy: A Meta-Analysis of Randomized Controlled Trials

    Cardiology in review

More on Non-HDL-C

All 28

What is obicetrapib linked with?

3

Studies link obicetrapib with 3 measures: new-onset diabetes, tolerability and adverse events.

New-onset diabetes

downin humans1OR 0.69

1 study
  1. Obicetrapib lowers the risk of new-onset diabetes in humans (Without diabetes at baseline; compared with placebo) (6.4% versus 8.5%; adjusted OR 0.69, 95% CI 0.47-1.03).

    “NoD occurred in 6.4% (obicetrapib) versus 8.5% (placebo) (adjusted OR 0.69, 95% CI 0.47-1.03), directionally consistent across glycaemic strata.”

    Human trialWithout diabetes at baseline; compared with placebo10 mg52 weeks38.8% womensn = 1,700

    Obicetrapib did not raise blood sugar in pooled trials

    European journal of preventive cardiology

More on New-onset diabetes

Tolerability

no changein humans1

1 study
  1. Obicetrapib is associated with tolerability in humans (heterozygous familial hypercholesterolemia on maximally tolerated lipid-lowering therapy).

    “Obicetrapib was well tolerated.”

    Human trialheterozygous familial hypercholesterolemia on maximally tolerated lipid-lowering therapy10 mg daily365 daysn = 354

    Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial

    Nature medicine

Adverse events

downin humans1RR 0.69

1 study
  1. Obicetrapib lowers the risk of adverse events in humans (versus placebo) (RR 0.69; 95% CI [0.49, 0.99]).

    “Obicetrapib had the lowest risk of overall adverse events (RR 0.69; 95% CI [0.49, 0.99])”

    Reviewversus placebon = 2,937

    Comparative efficacy of obicetrapib and anacetrapib in reducing low-density lipoprotein (LDL) levels: a network meta-analysis of clinical trials

    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences

Has obicetrapib been tested in people?

5 of 19 about aging

Yes: 9 trials in people have been published, and 18 trials are registered.

Every condition in trials

All 18

Who is developing obicetrapib?

2 companies: NewAmsterdam Pharma and A. Menarini International Licensing.

Companies
  • NewAmsterdam PharmaPhase 3lipidemia, type 2 diabetes
  • A. Menarini International LicensingPhase 3mixed dyslipidemia, hypercholesterolaemia

Trial sponsors

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 2Jan 2026: 2Feb 2026: 5Mar 2026: 3Apr 2026: 1May 2026: 0Jun 2026: 2Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 7Nov 2026: 124 papers in 12 months
European Journal of Preventive Cardiology

Obicetrapib did not raise blood sugar in pooled trials

Over 52 weeks, diabetes developed in 6.4% taking obicetrapib versus 8.5% taking placebo, but the results did not rule out no difference.Over 52 weeks, diabetes developed in 6.4% taking obicetrapib versus 8.5% taking placebo, but the results did not rule out no difference.

Randomized trial · 1,700 peopleObicetrapib

See all 32 papers on obicetrapib